Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIV - Takeaways - MDSpire

Viral Suppression in People With HIV Receiving Long-Acting Lenacapavir or Cabotegravir

By
Nathanael L. Gistand
Ishaan C. Mishra
Kyle Hunter
Megan J. Heise
Chesa Cox
Janet Grochowski
Francis Mayorga-Munoz
Jon Oskarsson
Mary Shiels
Matthew A. Spinelli
Monica Gandhi
October 8, 2026

Jama Network Open

Share

1

This retrospective, single-center case series included 46 treatment-experienced patients who initiated long-acting lenacapavir plus cabotegravir.
2

At lenacapavir initiation, 24 patients (52.2%) had viremia and 33 (71.7%) had baseline NNRTI resistance.
3

All 24 patients without baseline viral suppression achieved HIV RNA levels below 200 copies/mL by week 13.
4

Patients with baseline viral suppression maintained it, and suppression remained sustained over a median follow-up of 100 weeks.
5

The authors noted that the retrospective design, small sample, and single Ryan White–funded clinic limit generalizability.

Original Source(s)

Jama Network Open

Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIV

by Nathanael L. Gistand, Ishaan C. Mishra, Kyle Hunter, Megan J. Heise, Chesa Cox, Janet Grochowski, Francis Mayorga-Munoz, Jon Oskarsson, Mary Shiels, Matthew A. Spinelli, Monica Gandhi
October 8, 2026

Related Content

MDSpire News

CDC sees “no indication of a broader threat” from suspected Russia plague case

The suspected case remains unconfirmed as WHO and CDC monitor for signs of broader spread.

by Teraya Smith
October 7, 2026
3 min

The Pathologist

When Pathology Met a National Crisis

A personal account of how laboratory expertise can inform, reassure, and educate during a public emergency

by Gang He
October 9, 2026
4 min

The Pathologist

Aptamer Tests Face the Validation Challenge

Clinical adoption will require reproducibility, quality control, and evidence of diagnostic utility

October 6, 2026
3 min